Clinical Trial Details
| Trial ID: | L3163 |
| Source ID: | NCT00617565 |
| Associated Drug: | Biphasic Insulin Aspart |
| Title: | Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: biphasic insulin aspart|DRUG: biphasic human insulin |
| Outcome Measures: | Primary: 2-hr postprandial plasma glucose (PPPG) excursion, after 12 weeks of treatment | Secondary: HbA1c|Fasting plasma glucose |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 219 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2003-07-08 |
| Completion Date: | 2003-11-26 |
| Results First Posted: | |
| Last Update Posted: | 2017-02-24 |
| Locations: | Novo Nordisk Investigational Site, Beijing, Beijing, 100034, China|Novo Nordisk Investigational Site, Beijing, Beijing, 100730, China|Novo Nordisk Investigational Site, Beijing, Beijing, 100853, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, 200032, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, 200433, China|Novo Nordisk Investigational Site, Beijing, 100029, China |
| URL: | https://clinicaltrials.gov/show/NCT00617565 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|